Advanced Science (Nov 2022)
Patient‐Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy
- Shaobo Mo,
- Peiyuan Tang,
- Wenqin Luo,
- Long Zhang,
- Yaqi Li,
- Xiang Hu,
- Xiaoji Ma,
- Yikuan Chen,
- Yichao Bao,
- Xingfeng He,
- Guoxiang Fu,
- Xiaoya Xu,
- Xinxin Rao,
- Xiaomeng Li,
- Ruoyu Guan,
- Shengzhi Chen,
- Yun Deng,
- Tao Lv,
- Peiyuan Mu,
- Qiang Zheng,
- Simin Wang,
- Fangqi Liu,
- Yiwei Li,
- Weiqi Sheng,
- Dan Huang,
- Chen Hu,
- Jianjun Gao,
- Zhen Zhang,
- Sanjun Cai,
- Hans Clevers,
- Junjie Peng,
- Guoqiang Hua
Affiliations
- Shaobo Mo
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 P. R. China
- Peiyuan Tang
- Institute of Radiation Medicine Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Wenqin Luo
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 P. R. China
- Long Zhang
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 P. R. China
- Yaqi Li
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 P. R. China
- Xiang Hu
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 P. R. China
- Xiaoji Ma
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 P. R. China
- Yikuan Chen
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 P. R. China
- Yichao Bao
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 P. R. China
- Xingfeng He
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 P. R. China
- Guoxiang Fu
- Research and Early Development D1Med Technology (Shanghai) Inc Shanghai 200235 P. R. China
- Xiaoya Xu
- Institute of Radiation Medicine Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Xinxin Rao
- Institute of Radiation Medicine Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Xiaomeng Li
- Institute of Radiation Medicine Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Ruoyu Guan
- Institute of Radiation Medicine Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Shengzhi Chen
- Institute of Radiation Medicine Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Yun Deng
- Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Tao Lv
- Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Peiyuan Mu
- Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Qiang Zheng
- Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Simin Wang
- Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Fangqi Liu
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 P. R. China
- Yiwei Li
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 P. R. China
- Weiqi Sheng
- Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Dan Huang
- Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Chen Hu
- Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore MD 21218 USA
- Jianjun Gao
- Institute of Radiation Medicine Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Zhen Zhang
- Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 P. R. China
- Sanjun Cai
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 P. R. China
- Hans Clevers
- Hubrecht Institute KNAW and University Medical Center Utrecht P.O. Box 85500 Utrecht 3584 CT The Netherlands
- Junjie Peng
- Department of Colorectal Surgery Fudan University Shanghai Cancer Center Fudan University Shanghai 200032 P. R. China
- Guoqiang Hua
- Cancer Institute Fudan University Shanghai Cancer Center Shanghai 200032 P. R. China
- DOI
- https://doi.org/10.1002/advs.202204097
- Journal volume & issue
-
Vol. 9,
no. 31
pp. n/a – n/a
Abstract
Abstract There is no effective method to predict chemotherapy response and postoperative prognosis of colorectal cancer liver metastasis (CRLM) patients. Patient‐derived organoid (PDO) has become an important preclinical model. Herein, a living biobank with 50 CRLM organoids derived from primary tumors and paired liver metastatic lesions is successfully constructed. CRLM PDOs from the multiomics levels (histopathology, genome, transcriptome and single‐cell sequencing) are comprehensively analyzed and confirmed that this organoid platform for CRLM could capture intra‐ and interpatient heterogeneity. The chemosensitivity data in vitro reveal the potential value of clinical application for PDOs to predict chemotherapy response (FOLFOX or FOLFIRI) and clinical prognosis of CRLM patients. Taken together, CRLM PDOs can be utilized to deliver a potential application for personalized medicine.
Keywords
- chemotherapy response
- colorectal cancer liver metastasis
- patient‐derived organoid
- prognosis prediction
- tumor heterogeneity
